IntelGenx Technologies Corp.

Greetings and welcome to the Intelligenix fourth quarter and full year 2022 financial results conference call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If you wish to enter the queue to ask a question, please press star 1 on your phone at any time. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Stephen Kilmer, Investor Relations at Intelligenix. You may begin.

Thank you. Good afternoon, everyone, and thank you for joining us on today's call. With me on the line is Dr. Horst Hubei, Intelligenix's CEO, Andre Godin, our President and CFO, Dr. David Kadeko, the company's Head of Corporate Development and Strategic Alliances, Dr. Frank Pietrantonio, our Director of Clinical Research, and Tommy Kenney, our VP Legal Affairs and Intellectual Property and General Counsel. Before we begin, I would like to remind you that all amounts mentioned today are in U.S. dollars unless otherwise mentioned, and today's call may contain forward-looking information that represents our expectations as of today and accordingly are subject to change. We do not undertake any obligation to update any forward-looking statements, except those may be required by U.S. and Canadian securities laws. A number of assumptions were made by us in preparing these forward-looking statements, which are subject to risks and results may differ materially. Details on these risks and assumptions can be found in our filings with the U.S. and Canadian Securities Commissions. I'd now like to turn the call over to Dr. Dubey. Horst?

Thank you, Steve.